TB Diagnostics Market Size is projected to reach USD 2.14 Billion by 2030, growing at a CAGR of 5.56%: Straits Research
20. Juli 2022 14:40 ET
|
Straits Research
New York, United States, July 20, 2022 (GLOBE NEWSWIRE) -- The global TB diagnostics market had a market share of USD 1,337.30 million in 2021, according to the new report of Straits Research. It is...
Immune Network to Start Clinical Trial of Oral Mycobacterium Vaccae in Tuberculosis Patients
10. August 2011 05:00 ET
|
Immune Network Ltd
VANCOUVER, British Columbia, Aug. 10, 2011 (GLOBE NEWSWIRE) -- Immune Network Ltd., (Pink Sheets:IMMFF), reports that its business partner Immunitor company has launched a Phase 2 clinical trial of a...
Herbal TB Immunotherapy to be Presented at Hong Kong Conference
07. Juli 2011 10:33 ET
|
Immune Network Ltd
VANCOUVER, British Columbia, July 7, 2011 (GLOBE NEWSWIRE) -- Immune Network Ltd. (Pink Sheets:IMMFF) advises that clinical results from its new tableted form of Immunoxel (Dzherelo) product...
TB Immunotherapy Collaboration Agreement With Stirling Products and Zodiac Capital
30. Mai 2011 10:14 ET
|
Immune Network Ltd
Agreement to fast-track introduction of new Immunoxel/Dzherelo tablet as adjunct immunotherapy, especially for MDR-TB
VANCOUVER, British Columbia, May 30, 2011 (GLOBE NEWSWIRE) -- Immune...
Immunitor Presents Positive TB Treatment Data at African Conference
28. Februar 2011 06:22 ET
|
Immune Network Ltd
VANCOUVER, B.C., Feb. 28, 2011 (GLOBE NEWSWIRE) -- Immune Network Ltd. (Pink Sheets:IMMFF) advises that Immunitor will present latest results from its imm01 clinical trial in tuberculosis patients in...
Immunitor Releases Positive Results of TB Immunotherapy From Its Second Clinical Site
24. Januar 2011 04:43 ET
|
Immune Network Ltd
VANCOUVER, British Columbia, Jan. 24, 2011 (GLOBE NEWSWIRE) -- Immune Network Ltd., (Pink Sheets:IMMFF) a company in the business of development and commercialization of immune therapies, announced...
Immunitor Publishes Interim Data From Phase IIb imm01 TB Trial
30. Dezember 2010 04:41 ET
|
Immune Network Ltd
VANCOUVER, British Columbia, Dec. 30, 2010 (GLOBE NEWSWIRE) -- Immune Network Ltd. (Pink Sheets:IMMFF), advises that Immunitor has published data from the first half of the 120-patient imm01 clinical...
Immunitor Phase 2b imm01 Trial Enrollment Scheduled to Complete Next Week
01. November 2010 09:42 ET
|
Immune Network Ltd
VANCOUVER, British Columbia, Nov. 1, 2010 (GLOBE NEWSWIRE) -- Immune Network Ltd. (Pink Sheets:IMMFF), a company in the business of discovery and development of immune-based therapies, today announced...